Advertisement
Logos iRiS
Logos iRiS

Genome patent overturned

Yesterday the British High Court overturned a UK genome patent owned by biotech Human Genome Sciences. The patent covered the inflammation-linked protein neutrokine-alpha which is part of the tumor necrosis factor family of cytokines. The court overturned the patent, ruling that at the time its application was filed there was no practical application, the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/c2649894-5f54-11dd-91c0-000077b07658.html?nclick_check=1 Human Genome Science

By | August 1, 2008

Yesterday the British High Court overturned a UK genome patent owned by biotech Human Genome Sciences. The patent covered the inflammation-linked protein neutrokine-alpha which is part of the tumor necrosis factor family of cytokines. The court overturned the patent, ruling that at the time its application was filed there was no practical application, the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/c2649894-5f54-11dd-91c0-000077b07658.html?nclick_check=1 Human Genome Sciences applied for the patent in the mid-1990s. But the ruling might really affect Eli Lilly, who has spent $50 million developing an antibody to neutrokine-alpha and is looking to spend another $250 million bringing the therapy through clinical trials, the Times reported.
Advertisement
QIAGEN ingenuity
QIAGEN ingenuity

Popular Now

  1. First Data from Anti-Aging Gene Therapy
  2. The Two Faces of Fish Oil
    Notebook The Two Faces of Fish Oil

    The discovery of a tumor-protecting role for a fatty acid found in fish oil has sparked debate about the product’s safety.

  3. Locating Language within the Brain
  4. Brain Keeps Watch During Sleep
Advertisement
Gilson
Gilson
Advertisement
RayBioTech